| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CA125 |
| Entrez GeneID | 94025 |
| clone | 4C8C8 |
| WB Predicted band size | 1519kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MUC16 (AA: extra 1-200) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于MUC16抗体的3篇参考文献概览：
1. **"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress"**
作者：Felder M 等(2014)
摘要：该综述探讨了MUC16作为卵巢癌生物标志物CA125的临床意义，并分析了其作为抗体靶向治疗(如单克隆抗体和抗体-药物偶联物)的潜力，提出了其在肿瘤微环境调控中的作用机制。
2. **"Antibody-dependent cellular cytotoxicity by anti-MUC16 monoclonal antibodies against ovarian cancer"**
作者：Gubbels JAA 等(2010)
摘要：研究验证了靶向MUC16的单克隆抗体(如抗体OC125)通过激活自然杀伤(NK)细胞介导的抗体依赖性细胞毒性(ADCC)杀伤卵巢癌细胞的效果，为免疫治疗提供了实验依据。
3. **"Engineered anti-MUC16 antibody-drug conjugate potentiates the efficacy of chemotherapy in pancreatic cancer"**
作者：Konieczkowski DJ 等(2021)
摘要：开发了一种新型抗MUC16抗体-药物偶联物(ADC)，在胰腺癌模型中联合化疗显著抑制肿瘤生长，证明其通过靶向递送细胞毒素增强传统疗法的效果。
4. **"Molecular imaging of MUC16 expression with antibody-coupled nanoparticles in ovarian cancer"**
作者：Chen Y 等(2019)
摘要：利用抗MUC16抗体修饰的纳米探针实现卵巢癌特异性分子成像，证实其在体内外的高灵敏度和肿瘤靶向性，为无创诊断和术中导航提供了新方法。
**Background of MUC16 Antibodies**
MUC16. also known as CA125. is a high-molecular-weight glycoprotein belonging to the mucin family. It is characterized by a heavily glycosylated extracellular domain, transmembrane region, and cytoplasmic tail. MUC16 is overexpressed in epithelial cancers, particularly ovarian, pancreatic, and lung cancers, where it promotes tumor progression, metastasis, and immune evasion by interacting with cell adhesion molecules and signaling pathways.
MUC16 antibodies are tools designed to target specific epitopes on the MUC16 protein. In diagnostics, anti-MUC16 antibodies form the basis of the CA125 serum test, widely used for monitoring ovarian cancer recurrence and treatment response. However, limitations like false positives in benign conditions drive efforts to refine antibody specificity.
Therapeutically, MUC16 antibodies are explored for targeted cancer therapies. Examples include antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies, which leverage MUC16's cancer-specific expression to deliver cytotoxic agents or redirect immune cells against tumors. Challenges include overcoming MUC16's steric hindrance due to glycosylation and tumor heterogeneity.
Recent advances focus on engineering antibodies with enhanced affinity or bispecific designs to improve tumor targeting. Clinical trials, such as those involving DMUC5754A (an ADC), highlight the potential of MUC16-directed therapies. Ongoing research aims to optimize antibody utility in both liquid biopsies and precision oncology, balancing efficacy with reduced off-target effects.
×
